MyShare
Key factors
| sym | AKER |
| exch | US |
| MCap | 20.56M |
| Beta | 0.335 |
| EPS | -0.71 |
| Div date | 0000-00-00 |
Yesterday
| sym | AKER |
| exch | US |
| close | 642.0 |
| 50 Day MA | 6.492 |
| 200 Day MA | 5.225 |
| Target Price | 4.0 |
| Market Cap Mln | 20.56 |
Share statistics
| Shares Outstanding | 16.65M |
| Shares Float | 7805.6K |
| Percent Institutions | 13.40 |
| PercentInsiders | 12.51 |
| SharesShort | 1624.38K |
| Short Ratio | 5.05 |
| Shares Short Prior Month | 1944.38K |
| Short Percent | 10.40 |
Income
| Revenue TTM | 1577.03K |
| Revenue Per Share TTM | 0.395 |
| Quarterly Revenue Growth YOY | -40.5 |
| Gross Profit TTM | 478.74K |
| EBITDA | -6628.7K |
| Diluted Eps TTM | -4.98 |
earning
| Earnings Share | -0.71 |
Dividend
| Dividend Date | 2019-11-25 |
| Last Split Date | 2019-11-25 |
| Last Split Factor | 1:24 |
business
| Enterprise Value Revenue | 22.07 |
| Book Value /share | 3.916 |
| Price Book MRQ | 1.194 |
| Price Sales TTM | 7.616 |
| ReturnOnAssetsTTM | -0.32 |
| ReturnOnEquityTTM | -0.55 |
Sector
| Gic Group | Health Care Equipment & Services |
| Gic Industry | Health Care Equipment & Supplies |
| Gic Sector | Health Care |
| Gic Sub Industry | Health Care Equipment |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
Codes
| ISIN | US00973E3009 |
| CIK | 1321834 |
| Code | AKER |
| CUSIP | 00973E409 |
| Employer Id Number | 22-2983783 |
| CountryISO | US |
| Currency Code | USD |
| Currency Name | US Dollar |
| Exchange | NASDAQ |
| Currency Symbol | $ |
fund
| Type | Common Stock |
| UpdatedAt | 2021-08-22 |
| is Delisted | 1 |
| Delisted Date | 2021-06-29 |
| Home Category | Domestic |
info
| Fiscal Year End | December |
| Full Time Employees | 4.0 |
| IPODate | 2014-01-23 |
| International Domestic | International Domestic |
| MostRecent Quarter | 2021-03-31 |
Contact
| Name | Akers Biosciences Inc |
| Address | 1185 Avenue of the Americas, New York, NY, United States, 10036 |
| Country Name | USA |
| Phone | 856 848 8698 |
| Web URL | www.akersbio.com |
| Logo URL | /img/logos/US/AKER.png |
Akers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York.